Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
27/06/2024 | 14:36 | PR Newswire (US) | Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare | NASDAQ:ADTX | Aditxt Inc |
14/06/2024 | 22:01 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] | NASDAQ:ADTX | Aditxt Inc |
12/06/2024 | 22:35 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ADTX | Aditxt Inc |
07/06/2024 | 23:12 | Edgar (US Regulatory) | Form PRER14A - Preliminary Proxy Soliciting materials | NASDAQ:ADTX | Aditxt Inc |
29/05/2024 | 22:33 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:ADTX | Aditxt Inc |
20/05/2024 | 22:15 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ADTX | Aditxt Inc |
15/05/2024 | 12:50 | PR Newswire (US) | Evofem Biosciences Announces Financial Results for the First Quarter of 2024 | NASDAQ:ADTX | Aditxt Inc |
03/05/2024 | 20:14 | Business Wire | CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules | NASDAQ:ADTX | Aditxt Inc |
03/05/2024 | 15:00 | Business Wire | Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules | NASDAQ:ADTX | Aditxt Inc |
02/04/2024 | 14:30 | Business Wire | Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD) | NASDAQ:ADTX | Aditxt Inc |
27/03/2024 | 13:36 | PR Newswire (US) | Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 | NASDAQ:ADTX | Aditxt Inc |
07/03/2024 | 13:54 | PR Newswire (US) | For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy | NASDAQ:ADTX | Aditxt Inc |
04/03/2024 | 23:27 | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:ADTX | Aditxt Inc |
22/02/2024 | 23:21 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:ADTX | Aditxt Inc |
14/02/2024 | 15:26 | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] | NASDAQ:ADTX | Aditxt Inc |
01/02/2024 | 14:00 | PR Newswire (US) | Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 | NASDAQ:ADTX | Aditxt Inc |
30/01/2024 | 14:30 | Business Wire | Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications | NASDAQ:ADTX | Aditxt Inc |
23/01/2024 | 22:18 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:ADTX | Aditxt Inc |
18/01/2024 | 22:30 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:ADTX | Aditxt Inc |
08/01/2024 | 14:30 | Business Wire | Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million | NASDAQ:ADTX | Aditxt Inc |
05/01/2024 | 14:30 | Business Wire | Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules | NASDAQ:ADTX | Aditxt Inc |
02/01/2024 | 14:30 | Business Wire | Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement | NASDAQ:ADTX | Aditxt Inc |
29/12/2023 | 23:07 | Business Wire | Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules | NASDAQ:ADTX | Aditxt Inc |
12/12/2023 | 14:30 | Business Wire | Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally | NASDAQ:ADTX | Aditxt Inc |
16/11/2023 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:ADTX | Aditxt Inc |
13/11/2023 | 22:30 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ADTX | Aditxt Inc |
10/11/2023 | 00:04 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:ADTX | Aditxt Inc |
06/10/2023 | 14:00 | GlobeNewswire Inc. | Aditxt, Inc. to Present at 8th Annual Dawson James Conference | NASDAQ:ADTX | Aditxt Inc |
05/10/2023 | 14:00 | Business Wire | Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform | NASDAQ:ADTX | Aditxt Inc |
22/09/2023 | 16:19 | Edgar (US Regulatory) | Form RW - Registration Withdrawal Request | NASDAQ:ADTX | Aditxt Inc |